After uptake into liver cells, the antiemetic drugs tropisetron and ondansetron undergo metabolic inactivation by cytochrome P450 2D6 (CYP2D6). We investigated whether the hepatic organic cation transporter 1 (OCT1; SLC22A1) mediates cellular uptake and whether common OCT1 loss-offunction polymorphisms affect pharmacokinetics and efficacy of both drugs. Both tropisetron and ondansetron inhibited ASP þ uptake in OCT1-overexpressing HEK293 cells. Overexpression of wild-type, but not OCT1 loss-of-function variants, significantly increased tropisetron uptake. Correspondingly, patients with two loss-of-function OCT1 alleles had higher tropisetron plasma concentrations (n ¼ 59, Po0.04) and higher clinical efficacy (n ¼ 91, P ¼ 0.009) compared with carriers of fully active OCT1. Overexpression of OCT1 did not increase ondansetron uptake. Nevertheless, OCT1 genotypes correlated with pharmacokinetics (n ¼ 45, Po0.05) and clinical efficacy (n ¼ 222, Po0.02) of ondansetron, the effect size of OCT1 genotypes on pharmacokinetics and efficacy was greater for tropisetron than for ondansetron. In conclusion, in addition to the known effects of CYP2D6, OCT1 deficiency may increase efficacy of tropisetron and potentially of ondansetron by limiting their hepatic uptake.
Introduction
Although significant progress has been achieved in supportive care of cancer patients, many patients still suffer from chemotherapy-induced nausea and vomiting. Nausea and vomiting in cancer patients receiving moderate and high emetogenic chemotherapy are treated by serotonin receptor type (5-hydroxytryptamine 3 (5-HT 3 )) antagonists, such as tropisetron and ondansetron. 1 But still, approximately 15-30% of the patients do not respond sufficiently to the current antiemetic therapy. [1] [2] [3] One reason for the substantial differences in response may be genetic variability in drugs uptake and elimination.
The major elimination route of tropisetron and ondansetron is via metabolic inactivation by hepatic cytochrome P450 enzymes. Tropisetron is mainly, and ondansetron is partially, metabolized by cytochrome P450 2D6 (CYP2D6).
Genetic polymorphisms in CYP2D6 are known to affect the pharmacokinetics and the efficacy of these two 5-HT 3 antagonists, but these polymorphisms could explain only a small fraction of the interindividual variation in the efficacy of antiemetic treatment. 4 Compared with metabolism, less is known about the cellular uptake of the two 5-HT 3 antagonists.
As 5-HT 3 antagonists, like their natural counterpart serotonin, are moderately hydrophobic organic cations, human organic cation transporters (OCTs) may be responsible for their cellular uptake. The OCT isoform OCT1 is by far the most highly expressed OCT in the human liver. [5] [6] [7] The activity of OCT1 varies greatly between individuals because of common genetic polymorphisms, including the amino acids substitution arginine61-to-cysteine (R61C), cysteine88-to-arginine (C88R), glycine401-to-serine (G410S), glycine465-to-arginine (G465R) and a deletion of methionine420 (M420del). [7] [8] [9] In this study we analyzed whether OCT1 may mediate the cellular uptake of tropisetron and ondansetron and whether, and to what extent, genetic polymorphisms in OCT1 contribute to the variability in pharmacokinetics and therapeutic efficacy of tropisetron and ondansetron in cancer patients.
Materials and methods

Clinical study
The medical impact of OCT1 polymorphisms in the interaction with CYP2D6 polymorphisms was analyzed in a noninterventional clinical cohort study conducted at the University Medical Center Charité and the community hospital Krankenhaus Moabit, both in Berlin, Germany. The study was designed to evaluate the pharmacogenetics of cancer chemotherapy-induced nausea and vomiting in cancer patients receiving moderately to highly emetogenic chemotherapy. More detailed results on the impact of CYP2D6 polymorphisms in this context were published elsewhere. 4 This study included 270 patients with a mean age of 53.7 years (range 18-83 years; s.d. 13.3) who received either ondansetron-or tropisetron-based antiemetic treatment. Of these patients, 32% had breast cancer, 15.4% lung cancer, 14.2% non-Hodgkin's lymphoma, 4.9% multiple myeloma, 4.9% Hodgkin's disease and 28.1% miscellaneous other tumors. A second study sample included 60 cancer patients who received ondansetron antiemetic treatment. These patients were from the University Medical Center in Göttingen with a mean age of 53.4 years (range 19-81 years; s.d. 13). Of these patients, 66% had non-Hodgkin's lymphoma, 11% Hodgkin's disease, 3.1% multiple myeloma, 3.1% lung cancer and 16.8% miscellaneous other tumors.
Tropisetron (Navoban; Novartis Pharma, Basel, Switzerland) was given in a dosage of 5 mg once daily (n ¼ 96), and ondansetron (Zofran; GlaxoSmithKline, Brentford, UK) was given in a dosage of 8 mg twice daily (n ¼ 174 for the first and n ¼ 60 for the second study samples). Episodes of acute vomiting within the first 24 h after the start of chemotherapy were recorded by the patients in a diary, separately for the periods 0-4 h and 5-24 h after the start of the chemotherapy. A vomiting episode was defined as a single vomit or retch, or any number of continuous vomits or retches. Vomiting or retching had to be absent for at least 1 min to be calculated as different episodes according to the definition of the Italian Group for Antiemetic Research. The first study has been approved by the ethics committee of the Humboldt University Berlin and the second by the ethics committee of the Georg-August University in Göttingen. All patients have given written informed consent.
Pharmacokinetic measurements
Plasma concentrations of ondansetron and tropisetron were measured by high-performance liquid chromatography (HPLC) as described earlier. 10 The limit of quantification of this method was 1.25 ng ml -1 for tropisetron and 0.62 ng ml -1 for ondansetron. Interassay coefficient of variation for the concentration range between 1.9 and 15 ng ml -1 ranged from 8.5 to 13.7% for tropisetron and from 4.8 to 9.4% for ondansetron.
OCT1 genotyping
Genomic DNA was isolated from venous blood samples using an automated solid-phase extraction method according to the manufacturer's instructions (EZ1 DNA blood 350 ml kit used with the Bio-robot EZ1; both from Qiagen, Hilden, Germany). The genotyping of OCT1 (alternative gene name SLC22A1) was performed using a single-base primer extension method as described before. 7 The method was modified to genotype only the amino acid substitutions R61C, C88R, G401S, M420del and G465R. Standard quality control procedures were performed as described earlier, 11 showing 100% concordance in the sample calls.
The PHASE 2.1 software 12 was used to estimate the two haplotypes of each individual. Ten independent runs with different seed numbers were performed (used seeds 2, 1536, 2936, 3123, 4957, 5283, 6757, 7992, 8633 and 9045) in order to avoid seed-biased allele assignments.
Generation of HEK293 cell lines stably expressing OCT1 Cells overexpressing human OCT1 were generated by targeted integration of OCT1 complementary DNA into the genome of HEK293 cells using the Flp-In system (Invitrogen, Karlsruhe, Germany). Therefore, the OCT1 open reading frame was cut out with HindIII and EcoRV from an OCT1 expression plasmid pcDNA3::OCT1 (kindly supplied by Herman Koepsell and Valentin Gorboulev, University of Würzburg, Germany) and ligated into pcDNA5.1 plasmid opened with the same restriction enzymes. The resulting construct pcDNA5.1::OCT1 carries the wild-type OCT1. In addition, point mutations that represent the five lost-of-function amino acid substitutions in OCT1 were introduced into the pcDNA3::OCT1 construct by targeted mutagenesis. The complete OCT1 open reading frame was sequenced to confirm the correctness of the obtained OCT1 variants and then also re-cloned in the pcDNA5.1 plasmid. The different pcDNA5.1::OCT1 constructs were chromosomaly integrated in T-Rex HEK293 cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration; Invitrogen) using the Flp-In system according to the manufacturer's instructions. Successful genomic integration was confirmed by integration-specific PCR, and the overexpression of OCT1 was validated by real-time reverse transcriptase-PCR. Clones carrying the wild-type or the loss-of-function OCT1 variants showed on average 15-fold higher OCT1 mRNA expression compared with the control clone carrying genomic integration of the pcDNA5.1 vector alone. No significant differences were detected in the OCT1 mRNA expression between the wild-type and the lost-of-function variants.
Inhibition of ASP
þ uptake A total of 800 000 cells were plated per single well of 12-well plates (Nunc, Langenselbold, Germany), which had been precoated with poly-D-lysine (Sigma, Taufkirchen, Germany). The cells were grown for 48 h to reach confluence. Prior to the uptake measurements, the cells were washed twice with 1 ml warm (37 1C) Hank's buffered salt solution (HBSS, Invitrogen). The uptake was initiated by adding 0.5 ml warm (37 1C) HBSS that contained 1 mM ASP (4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide; Invitrogen) and varying concentrations of the respective inhibitory substance. The uptake was stopped after 3 min by adding 2 ml ice-cold HBSS. The HBSS medium was discarded and the cells were lysed in 0.5 ml RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40 and 0.25% (v/v) Na-deoxycholate; all purchased from Sigma). The amount of intracellular ASP þ was quantified by measuring the fluorescence at 485 nm excitation and 612 nm emission wavelengths using TECAN Ultra plate photometer (TECAN, Crailsheim, Germany).
Direct quantification of cellular uptake of tropisetron and ondansetron A total of 9 million cells were plated on 100 mm plates (BD Falcon, Heidelberg, Germany), which had been precoated with poly-D-lysine, and grown for 48 h to reach confluence. The number of used cells was based on the quantification limit of 1.25 ng ml -1 (4.5 pmol ml -1 for tropisetron) of the HPLC detection method, 10 assumed intracellular concentration of at least 1 mM and intracellular volume of 1 ml for 1 Â 10 6 cells. Prior to the uptake measurements, the cells were washed with 10 ml warm (37 1C) HBSS. The uptake was initiated by the addition of 5 ml warm (37 1C) HBSS containing 1 mM tropisetron or ondansetron. The uptake was stopped after 3 min by the addition of 20 ml ice-cold HBSS. The cells were washed twice with ice-cold HBSS and an aliquot was used for determination of total protein amount in the samples. The remaining cells were lysed and the proteins were precipitated by adding 1 ml of a mixture of 80% acetonitrile and 20% 0.05 M sodium acetate (pH 5.0). The samples were then centrifuged (10 min at 16 000 g) to pellet the cell debris, the supernatant was transferred into a 10 ml glass tube and evaporated to dryness at 40 1C under nitrogen. The residue was reconstituted in 200 ml of mobile phase (see below) and 50 ml was injected into the HPLC for quantification.
Tropisetron and ondansetron quantifications were performed using a modification of a previously described HPLC method. 10 Briefly, tropisetron and ondansetron were quantified using a LaChrom HPLC system (Merck Hitachi, Darmstadt, Germany) consisting of an interface (D-7000, Merck Hitachi), a pump (L-7100, Merck Hitachi), an automatic sampler (L-7200, Merck Hitachi), an ultraviolet detector (L-7400, Merck Hitachi) and a degasser (L-7614, Merck Hitachi). The compounds were separated at room temperature on a LiChrospher 100 reverse phase-18e (5 mm, 4 Â 150 mm) column with a LiChrospher 100CN guard column (5 mm, both from Merck) and quantified by ultraviolet detection at 284 nm for tropisetron and 305 nm for ondansetron. The mobile phase consisted of 20% acetonitrile and 80% 0.05 M sodium acetate buffer (pH 5.0) and was delivered at a flow rate of 1.5 ml min -1 . Tropisetron and ondansetron were detected as peaks with retention time of 5.7 and 4.3 min, respectively, and quantified using peak area with external standardization. The amount of intracellular tropisetron and ondansetron was normalized to the total number of cells.
Results
In vitro analyses of the OCT1-mediated uptake of tropisetron and ondansetron
In order to analyze whether OCT1 mediates the cellular uptake of tropisetron and ondansetron, wild-type OCT1 was overexpressed in HEK293, a human embryonic kidney cell line, using stable genome integration. Both tropisetron and ondansetron effectively competed the uptake of the wellestablished OCT1 substrate ASP þ . Tropisetron IC 50 was 8.5 ± 1.4 mM and ondansetron IC 50 was 63 ± 15.6 mM (Figure 1a) . The inhibition constants were comparable (ondansetron) or even tenfold lower (tropisetron) to the inhibition constant of quinine, a well-known OCT1 substrate. 13 The inhibition results corresponded to previously reported data, 13,14 but still do not clarify whether both drugs are substrates that are actively transported by OCT1, or act only as inhibitors of OCT1.
To confirm tropisetron and ondansetron as OCT1 substrates, we measured the intracellular uptake of both drugs using HPLC. Compared with cells transfected with blank plasmid, the OCT1-overexpressing cells showed a 2.3-fold increase in the intracellular accumulation of tropisetron (Po0.001, Student's t-test; Figure 1b ). This increase was completely reversible by MPP þ (1-methyl-4-phenylpyridinium), a specific model substrate and competitive inhibitor of OCT1. 13 In the same transport assay, the HEK293 cells showed high intracellular levels of ondansetron, and OCT1 overexpression did not result in additional increase of ondansetron uptake.
Second, we analyzed how common polymorphisms in the OCT1 gene may influence tropisetron uptake. Therefore, we overexpressed OCT1 variants carrying the five common amino acid substitutions, R61C, C88R, G401S, M420del or G465R, 7, 9 and compared their activity with the activity of the wild-type OCT1. Only those combinations of amino acid substitutions were analyzed that are natively found as polymorphisms in Caucasian populations. 7 In all variants, the uptake of tropisetron was reduced to the levels of the OCT1 non-expressing cells (Po0.001, one-way ANOVA; Figure 1b) . Thus, the in vitro data showed that OCT1 transported tropisetron and that the common loss-offunction polymorphisms in OCT1 abolished tropisetron transport. Although ondansetron inhibited the OCT1 transport, a direct OCT1-mediated uptake of ondansetron could not be measured in our in vitro system.
Effects of OCT1 polymorphisms on the pharmacokinetics and efficacy of tropisetron and ondansetron We analyzed whether the OCT1 genetic polymorphisms modified the pharmacokinetics and clinical effects of the 5-HT 3 antagonists. For that purpose, we utilized the data and DNA of patients from a previous study on the antiemetic treatment efficacy of tropisetron and ondansetron against chemotherapy-induced nausea and vomiting. 4 All 270 patients were Caucasians and had received standard doses of either tropisetron (n ¼ 96) or ondansetron (n ¼ 174) as prophylactic antiemetic treatment. DNA was not available from nine patients, and clinical data were incomplete for additional eight patients. Thus, data of 253 patients were available for the efficacy analyses. Thereof, 104 patients agreed to participate in a pharmacokinetic substudy. The 253 patients were genotyped for the five common amino acid substitutions in OCT1, that is, R61C, C88R, G401S, M420del or G465R. The genotypes obtained were in HardyWeinberg equilibrium and the allele frequencies corresponded to those previously reported in Caucasians. 7, 9 Corresponding to our results on tropisetron with the cell line experiments, we regarded as fully active those OCT1 alleles that lacked any of the five amino acid substitutions (Figure 2a ). In all, 31 patients (12%) carried two deficient OCT1 alleles, 96 (38%) carried only one deficient and one fully active OCT1 allele and 126 (50%) carried two fully active OCT1 alleles.
First, we analyzed the plasma concentrations of tropisetron and ondansetron in relation to the number of fully active OCT1 alleles. The plasma concentrations of tropisetron were measured at 3 h (n ¼ 59) and at 6 h (n ¼ 39) after administration. The plasma concentrations of ondansetron were measured at 3 h after administration (n ¼ 45). The plasma concentrations of tropisetron at 3 and 6 h after administration and of ondansetron at 3 h after administration were highest in the subgroups of patients lacking any fully active OCT1 allele and decreased with the increasing number of fully active OCT1 alleles (Po0.05; Figures 2b-d) .
Second, we analyzed the efficacy of antiemetic therapy in relation to the number of fully active OCT1 alleles. Antiemetic therapy efficacy was measured by the number of vomiting episodes in the first 24 h of the chemotherapy. Among the 253 patients, from whom the efficacy and genetic data were available, vomiting was observed in 59 patients (23.2%). Correspondingly to the increased plasma concentrations of tropisetron and ondansetron, the patients lacking any fully active OCT1 allele vomited more than three times less frequently than patients with one or two fully active OCT1 alleles (0.35 compared with 1.17 mean episodes of vomiting in the first 24 h, P ¼ 0.007; Figure 3a) . The effect was present both in the first 4 h and in the following 20 h after initiation of the chemotherapy (P ¼ 0.003 and P ¼ 0.037, respectively; data not shown). The effect was significant in the subgroup of patients who had received tropisetron (a mean of 0.08 episodes of vomiting in the non-carriers compared with a mean of 0.8 episodes in the carriers of fully active OCT1, P ¼ 0.009; Figure 3b ), and a similar strong trend in the same direction was present in the group of patients who had received ondansetron (P ¼ 0.062, data not shown). We confirmed the effect of OCT1 genotypes on ondansetron efficacy in an independent second sample of 60 patients. The patients lacking fully active OCT1 (n ¼ 8) did not vomit at all, whereas the patients with one or two fully active OCT1 alleles experienced 0.75 mean episodes of vomiting in the first 24 h (n ¼ 52). Combined analyses of the two groups who had received ondansetron showed a significant decrease in vomiting incidence in the patients lacking any fully active OCT1. A mean of 0.37 episodes of vomiting was observed in the group lacking fully active OCT1 compared with a mean of 1.27 episodes of vomiting observed in the carriers of one or two fully active OCT1 gene copies (P ¼ 0.018; Figure 3c ).
Finally, we analyzed the combined effects of OCT1 and CYP2D6 polymorphisms on the plasma concentrations and the efficacy of tropisetron and ondansetron. As shown earlier in the same sample of patients, high activity of CYP2D6 is associated with rapid elimination of the antiemetic drugs and poor antiemetic efficacy. 4 Therefore, to exclude confounding effects of CYP2D6 activity, we adjusted the effects of the OCT1 genotypes for the effects of the CYP2D6 genotypes using multiple linear regression. The patients were stratified into four groups according to their number of active CYP2D6 alleles: 0 active alleles (poor metabolizers), 1 (intermediate metabolizers), 2 (extensive metabolizers) and 3 and more active alleles (ultra-rapid metabolizers). After the adjustment for the number of active CYP2D6 alleles, the plasma concentrations of tropisetron remained significantly dependent on the OCT1 genotypes at both 3 and 6 h after the administration (P ¼ 0.02 and P ¼ 0.04, respectively). OCT1 genotype explained 8.1% of the variation in tropisetron plasma concentrations at 3 h and 11.3% at 6 h after administration (calculated as r 2 from linear regression analysis). CYP2D6 genotype explained 9.4% of the variation in tropisetron plasma concentrations at 3 h and 12% at 6 h after administration. The effect size of the OCT1 polymorphisms on tropisetron concentrations was lower than this of the CYP2D6 polymorphisms. The increases in the mean tropisetron concentrations between carriers of two deficient compared with two fully active OCT1 alleles were 4.9-fold at 3 h and twofold at 6 h after administration. The corresponding increases for two deficient versus two fully active CYP2D6 alleles were 11-fold and 2.8-fold. Also, the plasma concentrations of ondansetron remained significantly dependent on the OCT1 genotypes after adjustment for the effect of the CYP2D6 genotypes (P ¼ 0.04). OCT1 genotype explained 9% of the variation in ondansetron plasma concentrations (calculated as r 2 from linear regression analysis).
The effect of the OCT1 genotypes on antiemetic therapy efficacy also remained significant after adjustment for the CYP2D6 genotypes (Po0.03 in multiple linear regression analyses). OCT1 genotype explained 1.8% of the variation in frequencies of vomiting and CYP2D6 genotype explained only 1.2%. Also, the effect size of the OCT1 polymorphisms on vomiting was stronger than the effect size because of the CYP2D6 polymorphism. The difference in mean number of episodes of vomiting between carriers of two deficient versus two fully active OCT1 alleles was 76%, whereas the corresponding difference between carriers of two deficient versus two fully active CYP2D6 alleles was only 57%. The CYP2D6 gene dose-like effect was present only at the background of highly active OCT1 (two fully active OCT1 alleles, data not shown), which appeared mechanistically plausible: if the transport is limiting, the metabolism is less dependent on the intrinsic intracellular metabolic capacity. However, the sample size was too small for further in-depth analysis of the OCT1-CYP2D6 gene-gene interactions on tropisetron and ondansetron efficacy.
Discussion
In the past 30 years, convincing data have emerged about the impact of polymorphisms in cytochrome P450 enzymes on the pharmacokinetics and clinical effects of many drugs. 15, 16 However, before a drug can be metabolized, it must enter the cell, and the data presented here showed how polymorphisms in a transporter mediating the cellular uptake of a drug may modify pharmacokinetics and clinical effects. Specifically, our data suggest that patients lacking fully active OCT1 have impaired cellular uptake, reduced bio-inactivation and consequently a prolonged residence of the drug in the circulation, resulting in better efficacy. This was consistently shown for tropisetron, and several data indicated that this may also be the case for ondansetron. Effects of the loss-of-function polymorphisms in the liver uptake transporter OCT1 were comparable in strength with the effects of loss-of-function polymorphisms in the drugmetabolizing enzyme CYP2D6. 4 Thus, our data illustrate that the carrier-mediated hepatic uptake may be a ratelimiting factor for the metabolism of organic cationic drugs. Thus, the rate-limiting effect of genetic polymorphisms in OCT1 on the uptake and metabolism of organic cationic drugs may correspond to the well-studied effects of genetic polymorphisms in OATP1B1 on the metabolism of some organic anionic drugs. [17] [18] [19] [20] Our in vitro and in vivo data were consistent regarding the involvement of OCT1 in the cellular uptake, consequently in the pharmacokinetics and finally in the efficacy of tropisetron. First, tropisetron inhibited OCT1-mediated Figure 3 The therapy efficacy of tropisetron and ondansetron depends on organic cation transporter 1 (OCT1) genotype. Frequency of vomiting under treatment is shown in dependence on the number of fully active OCT1 alleles for all 253 patients of the first study sample (a) and separately for the patients treated with tropisetron (b) or ondansetron (c). For ondansetron, the data from the combined first and second study sample are shown. Bars represent mean and s.e. of vomiting episodes in the first 24 h after the chemotherapy began. The number of patients with different OCT1 genotypes is indicated (n).
transport. Second, OCT1 overexpression resulted in an increased uptake of tropisetron that was completely blocked by addition of the typical OCT1 substrate MMP þ acting as a competitive inhibitor of tropisetron transport. Third, genetic polymorphisms known to cause reduction or loss of OCT1 function with other substrates 21 also resulted in the loss of in vitro uptake of tropisetron (all in Figure 1) . Fourth, the drug plasma concentrations (Figure 2 ), and fifth, the frequency of vomiting of cancer patients under tropisetron treatment depended on the presence of loss-of-function OCT1 alleles (Figure 3) . Sixth, the in vivo effects of OCT1 could not be explained by the potentially confounding CYP2D6 genotypes.
Plasma concentrations and efficacy of ondansetron were also dependent on OCT1 genotypes, although the genotype effects were less strong compared with tropisetron. Ondansetron was also able to inhibit ASP uptake, but we were not able to measure directly the cellular uptake of ondansetron in vitro. One explanation for the consistently weaker in vivo and in vitro effects of ondansetron may be the lower pKa value of ondansetron (Table 1) . Thus, a higher fraction of ondansetron is not protonated in blood (or in the buffer used in the in vitro uptake experiments). In addition, ondansetron is more lypophilic (Table 1 ) and showed lower affinity to OCT1 than tropisetron (IC 50 of 63.9 compared with 8.6 mM; Figure 1a ). Taken together, these data suggest that ondansetron may be more prone to enter cells by passive diffusion than tropisetron, and may be less dependent on OCT1. Still, similar to tropisetron, loss-of-function OCT1 genotypes lead to increased plasma concentrations and efficacy of ondansetron. The last finding was observed in two independent samples, but again the effect of OCT1 variants on ondansetron was weaker than on tropisetron. There may be many additional differences between our in vitro cell culture system and the liver. An unknown alternative uptake transporter for ondansetron may be present in the HEK293 cells. Also, pH gradients or the OCT1 phosphorylation status, which may modulate substrate specificity, 22 may differ between the in vitro model and the human liver. However, this remains completely speculative at present.
The lack of any fully active OCT1 is a frequent condition. In our study, the patients lacking any relevant OCT1 activity were close to 12%. The observed OCT1 allele frequencies resembled those found in other Caucasians samples, 7 but may by lower in Africans and Asians (mostly because of the lower prevalence of the methionine 420 deletion in most of these populations). 9 Interestingly, the most common variation in OCT1 coding region, the methionine 420 deletion (allele OCT1*2), seems to have highly variable effects on OCT1 activity, depending on the substrate used. In our study, OCT1*2 showed no activity for tropisetron uptake (Figure 1 ), but showed close to 30% of the wild-type activity for metformin uptake 21 and close to 100% activity for MMP þ 8,9 and ASP þ (Tzvetkov et al., unpublished data). Thus, the frequency of individuals lacking active OCT1-mediated membrane transport may be dependent on the respective substrate.
Clinical consequences for patients lacking any fully active OCT1, and consequently having diminished bio-inactivation of tropisetron and ondansetron, may include not only increased incidence of adverse effects, but also improved efficacy of the antiemetic treatment. Constipation is a relevant adverse effect of 5-HT 3 antagonists, 23 and one might speculate that the risk for constipation may be increased in a case of OCT1 deficiency. However, generally this class of drugs has only relatively few adverse effects. 3 On the other hand, an increased antiemetic efficacy mostly without major adverse effects, which is expected according to our data in patients lacking active OCT1 function, is a therapeutic advantage that would not require any change in the dosing or scheduling of the antiemetic treatment. From that perspective, there would be no need for OCT1 genotyping of patients who would be treated with these drugs. However, as has been shown, carriers of three and more active CYP2D6 alleles, are at higher risk of antiemetic therapy failure. 4, 24, 25 These patients may indeed be particularly prone to antiemetic treatment failure if they carry in addition two fully active OCT1 alleles. This rare group of patients may profit from both OCT1 and CYP2D6 genotyping. In this rare group, a combined genotyping of OCT1 and CYP2D6 may have clinical consequences like dose escalation or selection of other 5-HT 3 antagonists that are not dependent on polymorphic CYP2D6. How pharmacokinetics and efficacy of tropisetron and ondansetron may be altered in CYP2D6 ultra-rapid metabolizers that lack any fully active OCT1 allele is an interesting question. Unfortunately, our sample size was too small to answer that question.
Drug-drug interactions on OCT1 may also account for additional interindividual variability in the hepatic uptake of tropisetron and ondansetron. A number of drugs, including the antidiabetic drug metformin, the antimalarial drug quinine and the chemotherapeutic drug oxaliplatin, but not cis-or carboplatin, are substrates for OCT1. 7, 13, 21, 26, 27 Although metformin and quinine are not typically co-administrated with tropisetron or ondansetron, patients treated with oxaliplatin may be expected to have reduced hepatocellular uptake and thus reduced metabolism and increased efficacy of tropisetron and potentially of ondansetron. However, there were no patients treated with oxaliplatin in our clinical sample to prove this assumption.
OCT1 may transport serotonin itself and, by its expression in the intestine, may mediate reuptake of serotonin released from the enterochromaffine cells upon cytostatic chemotherapy. 28 However, in this case OCT1 loss-of-function variants would be expected to result in an increased The pKa value of ondansetron is according to Maschru et al., 29 and all other physicochemical properties were calculated using ADMET Predictor Software 4.0 (Simulations Plus, Lancaster, CA, USA).
incidence of vomiting, which was apparently not observed ( Figure 3) . A possible explanation is that loss-of-function OCT1 polymorphisms affect the metabolism of 5-HT 3 antagonists stronger than the intestinal serotonin reuptake. In addition, quantitatively, the role of OCT1 in the reuptake of serotonin in intestine may be limited, and other transporters, such as the high-affinity serotonin reuptake transporter SERT, may be more important. 28 Finally, we should acknowledge some limitations of our study. Because of the limited sample size, we were not able to analyze interesting combinations of genotypes such as the CYP2D6 ultra-rapid metabolizers combined with the OCT1 low transporters. However, both tropisetron and ondansetron showed a consistent pattern in both pharmacokinetics and antiemetic effects, which confirms the combined impact of OCT1 and CYP2D6 in antiemetic treatment with ondansetron and tropisetron. Our data also suggest that the dependence on OCT1-mediated uptake into the liver may increase with the decrease in the lipophilicity of the drug. We think that the data presented here may stimulate further systematic research on the interactions between polymorphisms affecting cellular uptake and those affecting metabolism of drugs.
